Controlled trials of efficacy and safety of allergen-specific immunotherapy: historical aspects

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

в работе рассмотрены контролируемые исследования аллергенспецифической иммунотерапии (асит)
начиная с 80-х гг. до 2010 г. проанализированы отдельные двойные слепые, плацебо-контролируемые
исследования, мета-анализы, Кокрановские обзоры, согласительные документы, рекомендации, национальные и международные руководства. проведен сравнительный анализ эффективности и безопасности
подкожной и сублингвальной асит.

About the authors

Ol'ga Vadimovna Vorob'eva

Email: ptashka095@rambler.ru

I S Gushchin

O V Vorobyeva

Institute of Immunology

Institute of Immunology

I S Gushchin

Institute of Immunology

Institute of Immunology

References

  1. Abramson M.J., Puy R.M., Weiner J.M. Injection allergen immunotherapy for asthma. Cockrane Database Syst. Rev. 2010, v. (8), CD001186.
  2. Calderon M.A., Casale Th.B., Togias A. et al. Allergen-specific immunotherapy for respiratory allergies: From meta-analysis to regulation and beyond. J. Allergy Clin. Immunol. 2011, v. 127, p. 30-38.
  3. BSACI Position Paper on Immunotherapy. Clin. Exp. Allergy. 1993, v. 23 (Suppl. 3), p. 1-44.
  4. Frew A.J. Injection immunotherapy. British Society for Allergy and Clinical Immunology. Working Party. BMJ. 1993, v. 307, p. 919-923.
  5. Global Strategy for Asthma Management and Prevention. WHO/NHLBI workshop report. National Institutes of Health, National Heart, Lung and Blood Institute; 1995. Publication no. 95-3659.
  6. Guidelines for the use of allergen immunotherapy. Canadian Society of Allergy and Clinical Immunology. CMAJ. 1995, v. 152, p. 1413-1419.
  7. International Consensus Report on Diagnosis and Management of Rhinitis. International Rhinitis Management Working Group. Allergy. 1994 (Suppl. 19), p. 1-34.
  8. Malling H. Immunotherapy. Position paper of the EAACI. Allergy. 1988, v. 43 (Suppl. 6), p. 9-33.
  9. Malling H.J., Weeke B. Position paper: immunotherapy. (EAACI) The European Academy of Allergology and Clinical Immunology. Allergy. 1993, v. 48, p. 7-35.
  10. Van Cauwenberger P., Bachert C., Passalacqua G. et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy. 2000, v. 55, p. 116-134.
  11. Warner J.O. Hyposensitization in asthma: a review. J. R. Soc. Med. 1981, v. 74, p. 60-65.
  12. Bousquet J., Lockey R.F., Malling H.J. (Eds.) WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: 27-29 January 1997. Allergy. 1998, v. 53 (Suppl. 44), p. 1-42.
  13. Canonica G.W., Baena-Cagnani C.E., Bousquet J. et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy: a statement of a World Allergy Organisation (WAO) Taskforce. Allergy. 2007, v. 62, p. 317-324.
  14. Canonica G.W., Bousquet J., Casale T. et al. Sub-lingual immunotherapy: World Allergy Organisation Position Paper 2009. Allergy. 2009, v. 64, p. 1-59.
  15. Cox L., Nelson H., Lockey R. et al. Allergen immunotherapy: a practice parameter third update. J. Allergy Clin. Immunol. 2011, v. 127, p. 1-55. Epub 2010 Dec 3.
  16. Cox L., Li J.T., Nelson H. et al. Allergen immunotherapy: a practice parameter second update. J. Allergy Clin. Immunol. 2007, v. 120, p. 25-85.
  17. Immunotherapy. The Australian Society of Clinical Immunology and Allergy [Электронный ресурс]: www.allergy.org.au/ content/view/148/128/ (Дата обращения - 09.03.2011).
  18. Joint task force for practical parameters. American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter. Ann. Allergy, Asthma, Immunol. 2003, v. 90 (Suppl. 1), p. 1-40.
  19. Kleine-Tebbe J. et al. Die spezifische Immunotherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen: Leitlinie der Deutschen Gesellschaft fuer Allergologie und klinische Immunologie (DGAKI), des Aerzteverbandes Deutscher Allergologen (ADA) und der Gesellschaft fuer paediatrische Allergologie und Umweltmedizin (GPA). Allergol. J. 2006, v. 15, p. 56-74.
  20. Leith E. et al. Consensus guidelines on practical issues of immunotherapy - Canadian Society of Allergy and Clinical Immunology (CSACI). Allergy, Asthma, Clin. Immunol. 2006, v. 2, p. 47-61.
  21. Passalacqua G., Ledford D., Cox L. et al. Allergen-specific immunotherapy. In: WAO white book on allergy, p. 110-115 [Электронный ресурс]: www.worldallergy.org/publications (Дата обращения - 25.03.2011).
  22. Scadding G.K., Durham S.R., Mirakian R., Jones N.S., Leech S.C., Farooque S., et al. BSAСI guidelines for the management of allergic and non-allergic rhinitis. Clin. Exp. Allergy. 2008, v. 38, p. 19-42.
  23. Davies R.J. Immunotherapy in respiratory allergy. Thorax. 1983, v. 38, p. 401-407.
  24. Frankland A.W., Augustin R. Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component. The Lancet. 1954, v. 266, No. 1 (6821), p. 1055-1057.
  25. Lowell F.C., Franklin W. A double blind study of effectiveness and specificity of injection therapy in ragweed hay fever. N. Engl. J. Med. 1965, v. 273, p. 675-679.
  26. Воробьева О.В., Гущин И.С. Развитие метода аллергенспецифической иммунотерапии в период 20-60-х годов XX века - до обнаружения IgE. Рос. Аллергол. Журн. 2011, № 2, с. 3-12.
  27. Norman P.S., Lichtenstein L.M., Kagey-Sobotka A. et al. Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. J. Allergy Clin. Immunol. 1982, v. 70, p. 248-260.
  28. Bousquet J., Maasch H.J., Hejjaoui A. et al. Double-blind, placebo- controlled immunotherapy with grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular- weight preparations in rhinoconjunctivitis and asthma. J. Allergy Clin. Immunol. 1989, v. 84, p. 546-556.
  29. Olsen O.T., Larsen K.R., Jacobsen L. et al. A 1-year, placebocontrolled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy. 1997, v. 52, p. 853-859.
  30. Litwin A., Flanagan M., Entis G. et al. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. J. Allergy Clin. Immunol. 1997, v. 100, p. 30-38.
  31. Naclerio R.M., Proud D., Moylan B. et al. A double-blind study of the discontinuation of ragweed immunotherapy. J. Allergy Clin. Immunol. 1997, v. 100, p. 293-300.
  32. Adkinson N.F., Eggleston P.A., Eney D. et al. A controlled trial of immunotherapy for asthma in allergic children. 1997, v. 336, p. 324-332.
  33. Passalacqua G., Albano M., Riccio A.M. et al. Clinical and immunological effects of a rush sublingual immunotherapy to Parietaria species: a double-blind placebo-controlled trial. J. Allergy Clin. Immunol. 1999, v. 104, p. 964-968.
  34. Walker S.M., Pajno G.B., Torres Lima M. et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: A randomized, controlled trial. J. Allergy Clin. Immunol. 2001, v. 107, p. 87-93.
  35. Pajno G.B., Morabito L., Barberio G. et al. Clinical and immunological effects of long-term sublingual immunotherapy in asthmatic children sensitized to mite: a double blind study. Allergy. 2002, v. 55, p. 842-849.
  36. Torres L., Wilson D. et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trials. Clin. Exp. Allergy. 2002, v. 32, p. 507-514.
  37. Pajno G.B., Passalacqua G., Vita D. et al. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. Allergy. 2004, v. 59, p. 883-887.
  38. Khinci M.S., Poulsen L.K. et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized placebo controlled double blind study. Allergy. 2004, v. 59, p. 45-53.
  39. Marogna M., Spadolini I., Massolo A. et al. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: a clinical efficacy and more. Allergy. 2004, v. 59, p. 1205-1210.
  40. Frew A.J., Powell R.J. et al. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2006, v. 117, p. 319-325.
  41. Mauro M., Russello M., Incorvaia C. et al. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study. Eur. Ann. Allergy Clin. Immunol. 2007, v. 39, p. 119-122.
  42. Marogna M., Tomassetti D., Bernasconi A. et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann. Allergy Asthma Immunol. 2008, v. 101, p. 206-211.
  43. Abramson M.J., Puy R.M., Weiner J.M. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am. J. Resp. Crit. Care Med. 1995, v. 151, p. 969-974.
  44. Ross R.N., Nelson H.S. et al. Effectiveness of immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind placebo controlled studies. Clin. Ther. 2000, v. 22, p. 329-341.
  45. Ross R.N., Nelson H.S., Finegold I. Effectiveness of specific immunotherapy in the treatment of Hymenoptera venom hypersensitivity: a meta-analysis. Clin. Ther. 2000, v. 22, p. 351-358.
  46. Abramson M.J., Puy R.M., Weiner J.M. Allergen immunotherapy for asthma. Cockrane Database Syst. Rev. 2003, v. 4, CD001186.
  47. Wilson D.R., Torres L.M., Durham S.R. Sublingual immunotherapy for allergic rhinitis. Cockrane Database Syst. Rev. 2003, (2), CD002893.
  48. Wilson D.R., Torres Lima M. et al. Sublingual immunotherapy for allergic rhinitis: Systemic review and meta-analysis. Allergy. 2005, v. 60, p. 4-12.
  49. Olaguibel J.M., Alvarez Puebla M.J. Efficacy of sublingual allergen vaccination for respiratory allergy in children: conclusion from one meta-analysis. J. Investig. Allergol. Clin. Immunol. 2005, v. 15, p. 9-16.
  50. Calamita Z., Saconato H., Pela A.B. et al. Efficacy of sublingual immunotherapy in asthma: a systemic review of randomized- clinical trials using the Cockrane Collaboration method. Allergy. 2006, v. 61, p. 1162-1172.
  51. Penagos M., Passalacqua G., Compalati E. et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008, v. 133, p. 599-609.
  52. Abramson M.J., Puy R.M., Weiner J.M. Allergen specific immunotherapy for asthma (Cockrane Review) / In: Cockrane Library. 1998. Issue 3. Oxford: Update Software.
  53. Abramson M., Puy R., Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy. 1999, v. 54, p. 1022- 1041.
  54. Calderon M.A., Alves B., Jacobson M. et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cockrane Database Syst. Rev. 2007, (1), CD001936.
  55. Compalati E., Passalacqua G., Bonini M., Canonica G.W. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: result of a GA2LEN meta-analysis. Allergy. 2009, v. 64, p. 1570-1579.
  56. Penagos M., Compalati E., Tarantini F. et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann. Allergy Asthma Immunol. 2006, v. 97, p. 141-148.
  57. Клинические рекомендации. Аллергология / Под ред. Р.М. Хаитова, Н.И. Ильиной. М., «ГЭОТАР-Медиа». 2008, с. 193-206. Серия «Клинические рекомендации РААКИ».
  58. Гущин И.С., Читаева В.Г. Аллергия к насекомым: клиника, диагностика и лечение. М., «Фармарус Принт». 2003, с. 162-236.
  59. Гущин И.С., Курбачева О.М. Аллергия и аллергенспецифическая иммунотерапия. М., «Фармарус Принт Медиа». 2010, с. 110-226.
  60. Morris A. Allergen-specific immunotherapy - guidelines for the clinician. Allergy Society of South Africa [Электронный ресурс]: http://www.allergysa.org/immuno.htm (Дата обращения - 16.06.2008).
  61. Sabbah A., Hassoun S., Le Sellin J. et al. A double-blind, placebo- controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy. 1994, v. 49, p. 309-313.
  62. Scadding G.K., Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin. Allergy. 1986, v. 16, p. 483-491.
  63. Tari M.G., Mancino M., Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol. Immunopathol.(Madr.). 1990, v. 18, p. 277-284.
  64. Gidaro G.B., Marcucci F., Sensi L. et al. The safety of sublingual- swallow immunotherapy: an analysis of published studies. Clin. Exp. Allergy. 2005, v. 35, p. 565-571.
  65. Erny-Albrecht K. et al. Sublingual immunotherapy in allergic rhinitis and asthma: a review of recent clinical evidence. J. Appl. Res. 2007, v. 7, p. 17-31.
  66. Bucantz S.C., Bagg A.S., and Lockey R.F. Adverse effects and fatalities associated with subcutaneous allergen immunotherapy. In: Allergens and Allergen Immunotherapy. Ed. by R.F. Lockey, D.K. Ledford. 4th ed. Clinical Allergy and Immunology Series. Vol. 21. Informa Healthcare USA Inc. 2008, p. 455-468.
  67. Passalacqua G., Valovirta E. Adverse effects associated with sublingual immunotherapy. In: Allergens and Allergen Immunotherapy. Ed. by R.F. Lockey, D.K. Ledford. 4th ed. Clinical Allergy and Immunology Series. V. 21. Informa Healthcare USA Inc. 2008, p. 469-476.
  68. Lockey R.F., Benedict L.M., Turkeltaub P.C. et al. Fatalities from immunotherapy (IT) and skin testing (ST). J. Allergy Clin. Immunol. 1987, v. 79, p. 660-677.
  69. Reid M.J., Lockey R.F., Turkeltaub P.C. et al. Survey of fatalities from skin testing and immunotherapy 1985-1989. J. Allergy Clin. Immunol. 1993, v. 92, p. 6-15.
  70. Bernstein D.I., Wanner M., Borish L., Liss G.M. and the Immunotherapy Committee of the AAAAI. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J. Allergy Clin. Immunol. 2004, v. 113, p. 1129-1136.
  71. The Committee on the Safety of Medicine (CSM) Update: Desensitizing vaccines. Br. Med. J. 1986, v. 293, p. 948.
  72. Luederitz-Puchel U., Haustein D. Incidents following hyposensitization. Muench. med. Wschr. 1996, v. 138, p. 1-7.
  73. Amin H.S., Liss G.M., Bernstein D.I. Evaluation of near-fatal reactions in allergen immunotherapy injections. J. Allergy Clin. Immunol. 2006, v. 117, p. 169-175.
  74. Ragusa F.V., Passalacqua G., Gambardella R. et al. Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience. J. Investig. Allergol. Clin. Immunol. 1997, v. 7, p. 151-154.
  75. Ragusa F.V., Massolo A. Non-fatal systemic reactions to subcutaneous immunotherapy: a 20-year experience comparison of two 10-year periods. Allerg. Immunol. (Paris). 2004, v. 36, p. 52-55.

Statistics

Views

Abstract: 152

Article Metrics

Metrics Loading ...

Dimensions

PlumX


Copyright © Pharmarus Print Media, 2011



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies